I agree that this site is using cookies. You can find further informations here.
X
Shaw, AT
79  results:
Search for persons X
?
1

Optimizing Treatment for Patients With Anaplastic Lymphoma ..:

Dagogo‐Jack, I ; Shaw, AT ; Riely, GJ
Clinical Pharmacology & Therapeutics.  101 (2017)  5 - p. 625-633 , 2017
Link: https://doi.org/10.1002/..
 
?
2

Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Pro..:

Ou, S-H ; Solomon, BJ ; Shaw, AT...
issn:1556-0864.  , 2022
Link: http://hdl.handle.net/11..
 
?
3

Plain language summary of the CROWN study comparing lorlati..:

Solomon, BJ ; Bauer, TM ; de Marinis, F...
issn:1479-6694.  , 2021
Link: http://hdl.handle.net/11..
 
?
4

Intracranial and extracranial efficacy of lorlatinib in pat..:

Felip, E ; Shaw, AT ; Bearz, A...
issn:0923-7534.  , 2021
Link: http://hdl.handle.net/11..
 
?
5

National Institute for Health Research Health Informatics C..:

Smith, DA ; Wang, T ; Freeman, O...
doi:10.1136/bmjhci-2020-100145.  , 2021
Link: https://doi.org/10.1136/..
 
?
6

National Institute for Health Research Health Informatics C..:

Smith, DA ; Wang, T ; Freeman, O...
https://discovery.ucl.ac.uk/id/eprint/10137995/1/Nastouli_National%20Institute%20for%20Health%20Research%20Health%20Informatics%20Collaborative_VoR.pdf.  , 2020
Link: https://discovery.ucl.ac..
 
?
7

Entrectinib in ROS1 fusion-positive non-small-cell lung can..:

Drilon, A ; Siena, S ; Dziadziuszko, R...
https://discovery.ucl.ac.uk/id/eprint/10092955/3/Arkenau_Entrectinib%20in%20ROS1%20fusion-positive%20non-small-cell%20lung%20cancer.%20Integrated%20analysis%20of%20three%20phase%201-2%20trials_AAM.pdf.  , 2020
Link: https://discovery.ucl.ac..
 
?
8

Crizotinib in ROS1-rearranged advanced non-small-cell lung ..:

Shaw, AT ; Riely, GJ ; Bang, Y-J...
issn:0923-7534.  , 2019
Link: http://hdl.handle.net/11..
 
?
9

Time To Response In Patients With Advanced Anaplastic Lymph..:

Gadgeel S ; Shaw AT ; Barlesi F...
https://www.dovepress.com/time-to-response-in-patients-with-advanced-anaplastic-lymphoma-kinase--peer-reviewed-article-LCTT.  , 2019
Link: https://doaj.org/article..
 
?
10

Crizotinib versus Chemotherapy in Asian Patients with ALK-P..:

Nishio, M ; Kim, D-W ; Wu, Y-L...
issn:1598-2998.  , 2018
Link: http://hdl.handle.net/11..
 
?
11

Final results of the large-scale multinational trial PROFIL..:

Blackhall, F ; Camidge, DR ; Shaw, AT...
issn:2059-7029.  , 2017
Link: http://hdl.handle.net/11..
 
?
12

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 r..:

Shaw, AT ; Felip, E ; Bauer, TM...
issn:1470-2045.  , 2017
Link: http://hdl.handle.net/11..
 
?
13

Pooled Systemic Efficacy and Safety Data from the Pivotal P..:

Yang, JC-H ; Ou, S-HI ; De Petris, L...
Journal of Thoracic Oncology.  , 2017
Link: http://hdl.handle.net/10..
 
?
14

Pooled Systemic Efficacy and Safety Data from the Pivotal P..:

Yang, JC-H ; Ou, S-HI ; De Petris, L...
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, 12 (10), pp. 1552 - 1560.  , 2017
Link: https://repository.icr.a..
 
?
15

Activity and safety of ceritinib in patients with ALK-rearr..:

Kim, D-W ; Mehra, R ; Tan, DSW...
issn:1470-2045.  , 2016
Link: http://hdl.handle.net/11..
 
1-15